Nestlé splashes $1.4bn to revamp skincare business


Nestlé has bought the US and Canadian rights to lotions and potions used in “specialised medical skin treatments” from Valeant Pharmaceuticals in a $1.4 billion deal.

Under the agreement with Valeant, Nestlé gains the rights to Perlane, Emervel, Dysport and Sculptra products. It already has the use of these brands outside of the US and Canada. 

This deal in the fast-growing anti-aging market is the latest in Nestlé’s wider expansion into healthcare.

In March the company agreed to take over Galderma, its dermatology joint venture  with L’Oreal. It created a division called Nestlé Skin Health which will include the Galderma  operation and its Bübchen infant skincare business.

Nestlé chairman Peter Brabeck-Letmathe, said: “With this deal we have acquired key, strategic assets to extend Nestlé’s activities in  the field of specialised, medical skin treatments, providing consumers with life-enhancing scientific products.”